FDA extends review of Novo Nordisk's haemophilia A drug denecimig

Go back to FDA extends review of Novo Nordisk's haemophilia A drug denecimig

Form 6-K NOVO NORDISK A S For: Oct 02

October 5, 2026 6:02 AM EDT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

... More